Table 1 Demographics and baseline disease characteristics in open label extension period
GMB/GMB (N = 243) | PBO/GMB (N = 241) | |
|---|---|---|
Age, years | 37.2 (9.3) | 36.5 (9.8) |
Females, n (%) | 175 (72.0) | 180 (74.7) |
Race, n (%) | ||
Asian | 223 (91.8) | 222 (92.1) |
White | 20 (8.2) | 19 (7.9) |
Body mass index, kg/m2 | 23.4 (3.7) | 22.5 (3.1) |
Region | ||
China | 185 (76.1) | 187 (77.6) |
India | 38 (15.6) | 35 (14.5) |
Russia | 20 (8.2) | 19 (7.9) |
MHDs per month | 8.2 (2.8) | 8.3 (2.7) |
MHDs with acute medication use per month | 5.3 (5.0) | 5.0 (4.5) |
Migraine frequency, n (%) | ||
< 8 days/month | 110 (45.3) | 106 (44.0) |
≥ 8 days/month | 133 (54.7) | 135 (56.0) |
Duration of migraine illness, years | 12.7 (9.1) | 12.4 (8.2) |
ICHD MHDs per month | 6.3 (3.3) | 6.2 (3.2) |
Headache days per month | 9.1 (3.3) | 9.1 (2.9) |
Migraine attacks per month | 5.5 (1.8) | 5.6 (1.7) |
MSQ score | ||
Total | 61.0 (15.9) | 62.1 (15.3) |
Role Function-Restrictive | 55.3 (15.4) | 56.9 (14.8) |
Role Function-Preventive | 65.6 (18.6) | 66.1 (17.5) |
Emotional Function | 68.2 (22.2) | 68.7 (21.7) |
PGI-S | 4.5 (1.3) | 4.4 (1.3) |
MIDAS total score | 48.8 (37.4) | 45.0 (35.0) |